Insider buying last 90 days
No open-market insider purchases were filed for DNLI in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DNLI insider filing, plotted on the chart in Gekko.Open DNLI in Gekko
NASDAQ: DNLI
Denali Therapeutics (DNLI) Stock Analysis & Forecast
Oct 12 close
$18.95−0.50 (−2.6%)
Gekko Brief
AI summaryOct 12 closeDenali Therapeutics this week has centered on AVLAYAH, its newly FDA-approved enzyme replacement therapy for Hunter syndrome, described as the first new treatment for the condition in nearly 20 years and the first approved biologic designed to cross the blood-brain barrier. Coverage also revisited Q2 2026 results, with revenue of $3.60 million topping estimates while diluted EPS loss of $0.68 came in wider than expected, alongside Q3 revenue guidance of $10 million to $12 million pointing to a sharper commercial ramp. Sentiment across the coverage has been mixed, with some pieces flagging weak near-term momentum against a longer-term positive view, and analysts citing a 12-month target near $35.85.
The stock closed at $18.95, down 2.6%, sitting below both its 50-day average of $22.33 and 200-day average of $21.12, with a one-month return of -10.1% and a three-month return of -16.3%. The GekkoIndex reads 67.5, placing it in the Accumulation zone. Shares trade 25.7% below Gekko Fair Value of $25.50, with the 52-week range spanning $13.75 to $27.30.
The next earnings date falls on 5 November, 23 days out and after the close, inside a typical 20-trading-day holding window; the prior quarter's reaction was 1.7% following six beats in the last eight quarters, with an average absolute reaction of 5.8%. Smart money data shows no insider, Congress or unusual options activity in their respective windows. Seasonality over five years shows the next 20 trading days averaging +2.5%, positive in two of five years.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Denali Therapeutics price vs fair value
Close $18.95200-day averageGekko Fair Value $25.50
Denali Therapeutics quick facts
- Market cap
- $3.01B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$2.84
- Revenue, TTM
- $3.60M
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 1.02
- Volume
- 1.23M avg 1.98M
- 1-year return
- +17.2%
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±9.8%
- 50-day average
- $22.33
- 200-day average
- $21.12
- Next earnings
- Nov 5 after close
- Shares outstanding
- 159.8M
Denali Therapeutics swing-trade checklist
Denali Therapeutics scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $18.95 sits between the 50-day ($22.33) and 200-day ($21.12) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
67.5, Accumulation
Reading 67.5 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
25.7% below
Price is 25.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+2.5% on average
From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Denali Therapeutics stock chart and price history
Denali Therapeutics closed at $18.95 on Oct 12, 2026, +17.2% over the past year, inside a 52-week range of $13.75 to $27.30.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −10.1%
- 3 months
- −16.3%
- 6 months
- −2.4%
- 1 year
- +17.2%
The full DNLI chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DNLI in Gekko
Follow Denali Therapeutics through every session
Put DNLI on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DNLI in GekkoFree for 7 days. No credit card required.
About Denali Therapeutics
Denali Therapeutics works on medicines for diseases of the brain and nervous system, developing drug candidates aimed at conditions such as Parkinson's disease, Hunter syndrome, ALS, multiple sclerosis, Alzheimer's disease and cutaneous lupus erythematosus. Its pipeline includes several compounds at various clinical trial stages, from early Phase 1 work through to Phase 2 studies, each targeting a different neurodegenerative or related disorder.
The company does not work alone on this research. It has formed collaborations with a number of pharmaceutical and biotechnology partners, among them Takeda, Genentech, Sanofi, Genzyme and several F-star entities, along with academic and nonprofit ties to Harvard University and the Michael J. Fox Foundation, plus a diagnostics partnership with Centogene. A separate research and option arrangement with Secarna Pharmaceuticals supports work on antisense therapies for neurodegenerative conditions.
Denali Therapeutics was founded in 2013 and is headquartered in South San Francisco, California, having originally operated under the name SPR Pharma before adopting its current name in 2015. Its shares trade on the NASDAQ under the ticker DNLI.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- denalitherapeutics.com
Denali Therapeutics GekkoIndex: the smart money zone
Denali Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 67.5, in the Accumulation zone, up 0.2 points over five sessions.
67.5Accumulation
Up 0.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 47 | +0.7% | +6.7% | ||
| Accumulation (current zone) | 210 | +1.3% | +5.3% | ||
| Neutral | 397 | −0.2% | −0.3% | ||
| Distribution | 26 | +0.9% | −6.3% | ||
| Selling | 2 | Too few readings yet | |||
Average DNLI share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the DNLI price, zone by zone.Track DNLI in Gekko
Is Denali Therapeutics stock overvalued? Gekko Fair Value
Denali Therapeutics trades 25.7% below Gekko Fair Value of $25.50, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Denali Therapeutics shares are worth, recalculated every trading day.
$25.50
Gekko Fair Value, Oct 10, 2026
25.7% Undervalued
At the end of Aug 2026 the price was 25.4% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open DNLI in Gekko
Denali Therapeutics insider and Congress trading
No open-market insider purchases were filed for Denali Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DNLI were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DNLI, plotted on the chart in Gekko.Open DNLI in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds DNLI.
0added0opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Denali Therapeutics earnings: next date and track record
Denali Therapeutics reports on Nov 5, 2026, after the close (24 days away), and beat the EPS estimate in 6 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 24 days away
- EPS estimate
- −$0.37
- Revenue estimate
- $12.22M
6 of 8reports beat the EPS estimate
±5.8%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Denali Therapeutics completed its first full commercial quarter with AVLAYAH generating $3.6 million in net product revenue. AVLAYAH is the first FDA-approved biologic designed to cross the blood-brain barrier and the first new Hunter syndrome therapy in nearly 20 years. Two Alzheimer's programs (DNL628 targeting tau, DNL921 targeting Abeta) entered clinical development. Pro forma cash exceeded $1.1 billion following a priority review voucher sale.
- Guidance
- Initial clinical data from DNL628 and DNL921 Alzheimer's programs expected in 2027. Management highlighted strong launch momentum for AVLAYAH with continued growth anticipated, supported by over $1.1 billion in pro forma liquidity.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.68 est −$0.72 | $3.60M est $2.15M | +1.7% |
| May 7, 2026 | −$0.69 est −$0.71 | — est $2.57M | −3.9% |
| Feb 26, 2026 | −$0.73 est −$0.75 | — est $3.08M | −5.0% |
| Nov 6, 2025 | −$0.74 est −$0.76 | — est $2.86M | +0.9% |
| Aug 11, 2025 | −$0.72 est −$0.74 | — est $5.64M | −5.3% |
| May 6, 2025 | −$0.78 est −$0.70 | — est $2.97M | −10.4% |
| Feb 27, 2025 | −$0.67 est −$0.85 | — est $12.75M | −12.3% |
| Nov 6, 2024 | −$0.63 est −$0.63 | — est $11.62M | +7.1% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Denali Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Denali Therapeutics is $36.06, +90.3% from the last close, from 13 firms rating the stock in the last 90 days.
$36.06consensus 12-month target, +90.3% from the last close
Now $18.95Avg $36.06
Low $29High $42
Each firm’s latest rating in the last 90 days: 13 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Aug 25 | B. Riley Securities | $35 | +84.7% |
| Aug 11 | J.P. Morgan | $29 | +53.0% |
| Aug 7 | Robert W. Baird | $34 | +79.4% |
| Aug 7 | H.C. Wainwright | $42 | +121.6% |
| Aug 7 | UBS | $34 | +79.4% |
+5.3%average 20-day move after past Accumulation readings
+2.5%average move over the next 20 trading days in the last 5 years
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Denali Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Denali Therapeutics averaged +2.5% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +2.7% | 3 of 5 |
| Next 10 trading days | −3.0% | 2 of 5 |
| Next 15 trading days | −1.2% | 3 of 5 |
| Next 20 trading days | +2.5% | 2 of 5 |
| Next 30 trading days | −3.0% | 1 of 5 |
For scale, DNLI’s typical 20-trading-day move in either direction is about 9.8%.
Denali Therapeutics market cap and key statistics
Denali Therapeutics’s market cap is $3.01B and revenue of $3.60M over the last twelve months.
Valuation
- Market cap
- $3.01B
- EPS, TTM
- −$2.84
- Gekko Fair Value
- $25.50
Trading
- Volume
- 1.23M
- Avg volume, 20 days
- 1.98M
- 52-week high
- $27.30
- 52-week low
- $13.75
- Shares outstanding
- 159.8M
Financials
- Revenue, TTM
- $3.60M
- Profit margin
- 0%
- Return on equity
- -54.9%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.02
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±9.8%
Denali Therapeutics stock news this week
Coverage of Denali Therapeutics this week reads positive: 3 positive, 1 neutral and 2 negative headlines.
- Trading the Move, Not the Narrative: (DNLI) EditionStock Traders Daily, Oct 11
- Is Denali Therapeutics (DNLI) Reasonably Valued On Future Cash Flow?Yahoo Finance, Oct 10
- Denali Therapeutics stock stood 29.1 percent below its yearly highAD HOC NEWS, Oct 8
- Denali Therapeutics stock falls 3.16 percent as launch metrics guide debateAD HOC NEWS, Oct 7
- Denali Therapeutics stock costs EUR 17.77 while analysts cite USD 35.85AD HOC NEWS, Oct 5
- Denali Therapeutics Receives FDA Approval for AVLAYAH™, First New Treatment for Hunter Syndrome in Nearly 20 YearsQuiver Quantitative, Oct 5
Denali Therapeutics peers
Denali Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Denali Therapeutics stock FAQ
What is Denali Therapeutics’s market cap?
Denali Therapeutics’s market cap is $3.01B at the Oct 12, 2026 close of $18.95, with 159.8M shares outstanding.
What is the Denali Therapeutics stock forecast?
The consensus analyst 12-month price target for Denali Therapeutics is $36.06, +90.3% from the last close. Of the 13 firms that rated the stock in the last 90 days, 13 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Denali Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Denali Therapeutics is undervalued: the Oct 12, 2026 close of $18.95 is 25.7% below Gekko Fair Value of $25.50. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Denali Therapeutics report earnings next?
Denali Therapeutics is expected to report on Nov 5, 2026, after the market closes (24 days away). Analysts expect earnings of −$0.37 per share on revenue of $12.22M. Denali Therapeutics beat the earnings estimate in 6 of its last 8 reports, moving 5.8% on average across the report.
What is Denali Therapeutics’s 52-week high and low?
Denali Therapeutics’s 52-week high is $27.30 and its 52-week low is $13.75; it closed at $18.95 on Oct 12, 2026, +17.2% over the past year. Over the last five years the shares peaked at $56.08 on Nov 5, 2021.
Is Denali Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 2 as mixed (trend and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Denali Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.